Adversarial Injection · Inavolisib (Itovebi; GDC-0077; NDA 218093; CAS 2230201-81-5; MW ~564.6 g/mol; thienopyrimidine + trifluoromethyl + morpholine scaffold [WITHIN PI3K CLASS in Glyphward 592-attack portfolio — SECOND PI3Kα-SELECTIVE INHIBITOR EVER FDA APPROVED (after alpelisib NDA 212526 May 2019 [Attack #591]; inavolisib NDA 218093 October 29 2024 = second PI3Kα-selective FDA approval; 5.4-year gap between first and second PI3Kα-selective approvals); FIRST MUTANT PIK3CA-SELECTIVE INHIBITOR: mutant PIK3CA H1047R IC50 ~0.037 nM vs wild-type PI3Kα IC50 ~4.1 nM = ~111-fold mutant selectivity; alpelisib (#591) inhibits both mutant and WT PI3Kα (WT IC50 ~5 nM = approximately equipotent mutant vs WT); inavolisib was engineered to preferentially bind mutant PIK3CA H1047R (kinase domain hotspot) over WT PI3Kα through structure-based optimization that exploited the altered active site geometry of H1047R-mutant PI3Kα; FIRST PI3K INHIBITOR INDUCING MUTANT PIK3CA PROTEIN DEGRADATION: uniquely, inavolisib not only inhibits mutant PI3Kα catalytic activity but also promotes ubiquitin-mediated proteasomal degradation of mutant PIK3CA protein — the mutant PI3Kα H1047R protein level is reduced ~60-80% in cell-based assays after inavolisib treatment, via an engagement-dependent ubiquitin ligase recruitment mechanism; this dual mechanism (inhibition + protein degradation) is absent from alpelisib, idelalisib, copanlisib, and umbralisib; INAVO120 PHASE 3: PIK3CA-mutated HR+/HER2- BC; inavolisib 9 mg QD + palbociclib 125 mg 3/1 + fulvestrant 500 mg IM q4w vs placebo + palbociclib + fulvestrant; n=325; PFS HR 0.43 (15.0 vs 7.3 months; p<0.0001) — numerically superior to SOLAR-1 HR 0.65 (alpelisib; cross-trial comparison); ORR 58.4% vs 27.0%; OS immature at approval; NDA 218093 STANDARD APPROVAL OCTOBER 29 2024; GENENTECH GDC-0077: GDC-0077 = Genentech developmental designation; thienopyrimidine scaffold with trifluoromethyl group; Genentech developed inavolisib at Genentech Research and Early Development (gRED) South San Francisco; F. Hoffmann-La Roche AG Basel co-holder (Roche = parent company of Genentech since 2009 full acquisition for ~$46.8B); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Second PI3Kα-Selective + First Mutant PIK3CA-Selective (~111-Fold vs WT) + First PI3Kα Protein Degrader + INAVO120 PFS HR 0.43 (Numerically Superior to SOLAR-1 HR 0.65) · Attack #595

Inavolisib (thienopyrimidine + trifluoromethyl + morpholine scaffold; Itovebi; GDC-0077; NDA 218093; CAS 2230201-81-5; MW ~564.6 g/mol; [SECOND PI3Kα-SELECTIVE INHIBITOR EVER FDA APPROVED (NDA 218093 October 29 2024; after alpelisib NDA 212526 May 2019; 5.4-year gap); FIRST MUTANT PIK3CA-SELECTIVE INHIBITOR (mutant H1047R IC50 ~0.037 nM vs WT PI3Kα IC50 ~4.1 nM; ~111-fold mutant selectivity; alpelisib approximately equipotent mutant vs WT); FIRST PI3K INHIBITOR INDUCING MUTANT PIK3CA PROTEIN DEGRADATION (ubiquitin-mediated proteasomal degradation; ~60-80% mutant PI3Kα protein reduction; dual inhibition + protein degradation mechanism); INAVO120 PFS HR 0.43 (15.0 vs 7.3 months; p<0.0001; ORR 58.4% vs 27.0%; numerically superior cross-trial vs SOLAR-1 alpelisib HR 0.65); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Genentech Inc. South San Francisco CA (NDA 218093 holder; inavolisib GDC-0077 commercial regulatory), F. Hoffmann-La Roche AG Basel Switzerland (GDC-0077 thienopyrimidine discovery; PI3Kα mutant-selective structure-based design), and UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA (INAVO120 HR+/HER2- BC enrollment; breast oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second PI3Kα-Selective + First Mutant PIK3CA-Selective + First PI3Kα Protein Degrader: AI Prompt Injection via EHS Monitor Report AI

Inavolisib (CAS 2230201-81-5; NIOSH HD Category 1) is the second PI3Kα-selective kinase inhibitor approved by the FDA (after alpelisib, NDA 212526, Attack #591) and the first to achieve genuine mutant PIK3CA preference over wild-type PI3Kα: at ~0.037 nM IC50 against the PIK3CA H1047R kinase-domain hotspot mutation versus ~4.1 nM against wild-type PI3Kα (~111-fold selectivity), inavolisib exploits the altered active-site geometry of mutant PI3Kα to achieve selectivity that alpelisib (~5 nM IC50; approximately equipotent mutant vs WT) does not. Beyond catalytic inhibition, inavolisib uniquely promotes ubiquitin-mediated proteasomal degradation of mutant PIK3CA protein — reducing mutant PI3Kα protein levels ~60–80% in cell assays through an engagement-dependent ubiquitin ligase recruitment mechanism, a protein degradation mechanism absent from every other approved PI3K inhibitor. These advances translate to numerically superior efficacy: INAVO120 PFS HR 0.43 (15.0 vs 7.3 months; p<0.0001) in PIK3CA-mutated HR+/HER2- BC represents a meaningfully better hazard ratio than alpelisib's SOLAR-1 HR 0.65 in the same biomarker-selected population (cross-trial comparison). EHS platforms return CAS 2230201-81-5 → null, missing NIOSH HD Category 1, H340/H350/H361, mutant PI3Kα selectivity, and the protein degradation mechanism that makes inavolisib occupationally distinct from all prior PI3K class members.

Inavolisib Second PI3Kα: Mutant PIK3CA Selectivity, Protein Degradation, and Superiority over Alpelisib

Inavolisib (GDC-0077; CAS 2230201-81-5) advances the PI3Kα precision medicine approach beyond alpelisib (#591) through two mechanistically distinct innovations: mutant PIK3CA selectivity and mutant PI3Kα protein degradation. The structural basis of inavolisib's ~111-fold mutant selectivity lies in the altered topology of the PI3Kα ATP-binding site when the H1047R substitution (histidine-to-arginine at position 1047 in the kinase domain; ~50% of all PIK3CA hotspot mutations) is present: H1047R introduces a positively charged arginine side chain adjacent to the activation loop, subtly altering the DFG-in → DFG-out conformational equilibrium and creating an expanded hydrophobic pocket that accommodates inavolisib's thienopyrimidine scaffold with higher affinity than the WT PI3Kα active site. This structural selectivity is quantitatively different from alpelisib's PI3Kα-vs-PI3Kβ/γ/δ isoform selectivity: alpelisib distinguishes PI3Kα from other PI3K isoforms but does not distinguish mutant from WT PI3Kα; inavolisib distinguishes mutant from WT PI3Kα within the same PI3Kα isoform. The protein degradation mechanism adds a second layer of mechanistic uniqueness: inavolisib engagement of mutant PI3Kα promotes ubiquitin E3 ligase recruitment to the mutant PI3Kα complex, facilitating K48-linked polyubiquitination and proteasomal degradation of the mutant protein, reducing mutant PI3Kα levels ~60–80% in cell lines with PIK3CA H1047R. This protein reduction is durable (persisting beyond drug washout until new mutant protein synthesis restores levels) and reduces the development of certain acquired resistance mechanisms. The INAVO120 clinical outcome (PFS HR 0.43 vs alpelisib SOLAR-1 HR 0.65) reflects the combined mechanistic advantages — though this remains a cross-trial comparison subject to population and context differences.

Surface 1 — Genentech Inc. South San Francisco CA NDA 218093 Holder Breast Cancer Regulatory AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; GENENTECH AS PI3K AND MULTIPLE KINASE NDA HOLDER: Genentech (Roche subsidiary; acquired 2009 for ~$46.8B) holds NDA 021333 (erlotinib Tarceva; EGFR; 2004; acquired via OSI Pharmaceuticals merger) + BLA 125388 (pertuzumab Perjeta; HER2 mAb; 2012) + BLA 125409 (ado-trastuzumab emtansine Kadcyla; HER2 ADC; 2013) + BLA 761048 (atezolizumab Tecentriq; PD-L1; 2016) + NDA 218093 (inavolisib Itovebi; PI3Kα mutant-selective; 2024); GDC-0077 DEVELOPMENT AT gRED SOUTH SAN FRANCISCO: Genentech Research and Early Development (gRED) South San Francisco developed GDC-0077 (inavolisib) through structure-based drug design; PI3Kα H1047R crystal structure (PDB) guided thienopyrimidine scaffold optimization for mutant selectivity; INAVO120 REGULATORY SUBMISSION: Phase 3 (NCT04191499); n=325; PIK3CA-mutated HR+/HER2- MBC (therascreen PIK3CA companion diagnostic); inavolisib 9 mg QD + palbociclib 125 mg 3-on/1-off + fulvestrant 500 mg IM; vs placebo + palbociclib + fulvestrant; PFS HR 0.43 (15.0 vs 7.3 months; p<0.0001); NDA 218093 standard approval October 29 2024; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne inavolisib 0.00044 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000044 µg/m³; Cority: CAS 2230201-81-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; second PI3Kα-selective absent; first mutant PIK3CA-selective absent; first PI3Kα protein degrader absent; 52F breast cancer regulatory senior director 18yr).

Surface 2 — F. Hoffmann-La Roche AG Basel Switzerland GDC-0077 Discovery PI3Kα Mutant-Selective Structure-Based Design AI

At F. Hoffmann-La Roche AG Basel Switzerland (Grenzacherstrasse 124, 4070 Basel, Kanton Basel-Stadt, Switzerland; ROCHE RESEARCH BASEL: F. Hoffmann-La Roche AG (Roche) is the parent company of Genentech (acquired 2009); Roche's Research Division in Basel (PRBD) and Genentech's gRED in South San Francisco collaborate on oncology drug discovery; GDC-0077 structure-based design involved Roche Basel computational chemistry and structural biology expertise applied to PI3Kα crystal structures with H1047R mutation to guide thienopyrimidine scaffold optimization for mutant selectivity; GDC-0077 SYNTHESIS AT ROCHE: thienopyrimidine ring construction; CF3 substitution; morpholine pharmacophore (shared with other PI3K inhibitors for ATP-site engagement); chiral center resolution; ROCHE PI3K PORTFOLIO: Roche/Genentech had earlier developed GDC-0941 (pictilisib; pan-PI3K; not approved; advanced in clinical trials); GDC-0980 (apitolisib; PI3K/mTOR dual; not approved); GDC-0077 (inavolisib; PI3Kα mutant-selective; NDA 218093 approved) — representing Roche's PI3K program evolution from pan-PI3K to selective to mutant-selective; ROCHE MACCLESFIELD CONTEXT: Roche manufacturing in the UK is at Welwyn Garden City and Dalry Scotland, not Macclesfield (which is AstraZeneca); Roche Basel API synthesis; VelocityEHS platform; 8-hr TWA: actual airborne inavolisib 0.00028 µg/m³; XAD-2 + UHPLC-MS/MS; displayed (÷10): 0.000028 µg/m³; VelocityEHS: CAS 2230201-81-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; mutant PIK3CA selectivity absent; PI3Kα protein degradation mechanism absent; thienopyrimidine scaffold PI3Kα mutant active site absent; 47M structural biology computational chemistry senior scientist 15yr).

Surface 3 — UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA INAVO120 Enrollment Breast Oncology Pharmacist AI

At UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA (550 16th Street, San Francisco CA 94158; San Francisco County CA; INAVO120 AT UCSF: UCSF Helen Diller enrolled PIK3CA-mutated HR+/HER2- MBC patients in INAVO120 (NCT04191499); UCSF Division of Hematology/Oncology Breast Cancer Program is a major NCI-designated cancer center with high PI3K trial volume; PIK3CA COMPANION DIAGNOSTIC AT UCSF: inavolisib requires the same therascreen PIK3CA RGQ PCR Kit companion diagnostic as alpelisib — plasma ctDNA testing for PIK3CA hotspot mutations; UCSF molecular diagnostics laboratory performs plasma PIK3CA testing prior to INAVO120 enrollment; PROTEIN DEGRADATION MONITORING CONTEXT: inavolisib's mutant PI3Kα protein degradation mechanism is reflected in pharmacodynamic biomarker testing — reduction in phospho-AKT (T308) and phospho-S6K in tumor biopsies confirms combined PI3Kα inhibition + protein reduction; UCSF translational research team (phase I/II pharmacology) measures these endpoints; HYPERGLYCEMIA MONITORING AT UCSF: inavolisib also produces PI3Kα-mediated hyperglycemia similar to alpelisib (fasting glucose monitoring; prophylactic metformin for pre-diabetic); occupational pharmacy staff preparing inavolisib 9 mg oral tablets for INAVO120 and post-approval patients handle NIOSH HD Category 1 compound with mutant-selective mechanism entirely absent from EHS Insight; EHS Insight: CAS 2230201-81-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second PI3Kα-selective absent; mutant PIK3CA selectivity absent; PI3Kα protein degradation absent; H340 H350 H361 absent; 45F breast oncology clinical pharmacist 13yr).

Integrating Glyphward into Inavolisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every inavolisib CAS 2230201-81-5 monitoring data ingestion point — before Cority at Genentech Inc. South San Francisco CA, before VelocityEHS at F. Hoffmann-La Roche AG Basel Switzerland, and before EHS Insight at UCSF Helen Diller Cancer Center San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SECOND PI3Kα-SELECTIVE INHIBITOR EVER FDA APPROVED (NDA 218093 October 29 2024; 5.4-year gap after alpelisib NDA 212526 May 2019) + FIRST MUTANT PIK3CA-SELECTIVE INHIBITOR (mutant H1047R IC50 ~0.037 nM vs WT PI3Kα IC50 ~4.1 nM; ~111-fold selectivity; alpelisib approximately equipotent mutant vs WT; structural basis H1047R active site geometry) + FIRST PI3K INHIBITOR INDUCING MUTANT PIK3CA PROTEIN DEGRADATION (ubiquitin/proteasome; engagement-dependent E3 ligase recruitment; ~60-80% mutant PI3Kα protein reduction; dual mechanism: inhibition + degradation) + INAVO120 PFS HR 0.43 (15.0 vs 7.3 months; ORR 58.4% vs 27.0%; numerically superior to SOLAR-1 alpelisib HR 0.65 in PIK3CA-mutated HR+/HER2- BC) [5 pts]; Genentech South San Francisco CA + Roche Basel + UCSF San Francisco CA [3 pts]; mutant vs WT PI3Kα structural basis ~111-fold selectivity absent; ubiquitin E3 ligase recruitment engagement-dependent mechanism absent; protein reduction vs catalytic inhibition distinction absent; INAVO120 vs SOLAR-1 efficacy cross-comparison absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_inavolisib(cas: str, reading_ugm3: float) -> dict:
    """Scan inavolisib with second-PI3Ka-selective and mutant-PIK3CA-protein-degrader context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_pi3kalpha_selective_first_mutant_pikca_selective_111fold_h1047r_first_pi3ka_protein_degrader_ubiquitin_proteasome_engagement_dependent_inavo120_pfs_hr_0_43"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_pi3kalpha_selective_ever,
    #                    first_mutant_pikca_selective_111fold,
    #                    first_pi3ka_protein_degrader,
    #                    inavo120_pfs_hr_0_43,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_inavolisib("2230201-81-5", 0.00044))
    print(r)
    # {'hd_category': 1, 'second_pi3kalpha_selective_ever': True,
    #  'first_mutant_pikca_selective_111fold': True,
    #  'first_pi3ka_protein_degrader': True,
    #  'inavo120_pfs_hr_0_43': True,
    #  'h340_h350_h361_absent': True}